Clanotech Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Out of Business

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Out of Business

Clanotech General Information

Description

Developer of pharmaceuticals designed to treat cancer and age-related muscular degeneration. The company's pharmaceuticals are strategy spans from indications with orphan drug opportunities, enabling medical professionals to treat age-related muscular degeneration (AMD).

Contact Information

Website
clanotech.se
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Fogdevreten 2
  • 171 65 Solna
  • Sweden
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • Fogdevreten 2
  • 171 65 Solna
  • Sweden

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Clanotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 02-Jun-2022 Completed Out of Business
2. Secondary Transaction - Private 01-Jul-2016 Completed Generating Revenue
1. Later Stage VC 13-Feb-2013 Completed Generating Revenue
To view Clanotech’s complete valuation and funding history, request access »

Clanotech Patents

Clanotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20150031723-A1 Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases Active 05-Jan-2012
US-9376393-B2 Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases Active 05-Jan-2012
WO-2013103317-A1 Quinoline compounds which are anti-angiogenic integrin alpha5 betal inhibitors for use in the treatment of fibrosis or fibrosis-related diseases Inactive 05-Jan-2012
WO-2010133672-A1 Derivatives of quinoline-3-carboxylic acid and their medical use Inactive 20-May-2009
AU-2010251134-A1 Substituted quinolines for use as vegf inhibitors Inactive 20-May-2009 C07D401/12
To view Clanotech’s complete patent history, request access »

Clanotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Clanotech FAQs

  • When was Clanotech founded?

    Clanotech was founded in 2005.

  • Where is Clanotech headquartered?

    Clanotech is headquartered in Solna, Sweden.

  • What is the size of Clanotech?

    Clanotech has 2 total employees.

  • What industry is Clanotech in?

    Clanotech’s primary industry is Drug Discovery.

  • Is Clanotech a private or public company?

    Clanotech is a Private company.

  • What is Clanotech’s current revenue?

    The current revenue for Clanotech is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process